🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs Addiction Counsellors of Ireland Launch Strategic Plan 2026–2029 to Prepare for CORU Regulation Ireland Funds €426,000 Behavioral App for Alcohol Reduction Amid Record Treatment Demand A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs Addiction Counsellors of Ireland Launch Strategic Plan 2026–2029 to Prepare for CORU Regulation Ireland Funds €426,000 Behavioral App for Alcohol Reduction Amid Record Treatment Demand
Markets · 15 min delay
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
ISEQ9,241.3▲ +0.62%
NBI4,187.6▲ +1.14%
PFE28.42▼ -0.38%
AZN74.18▲ +0.81%
NVO103.55▲ +2.07%
ROG261.40▼ -0.55%
ABBV174.92▲ +0.29%
EUR/USD1.0842▼ -0.12%
Updated 04 Jul 2026 · HPRA open data

Irish Medicines Database

Every medicine authorised for the Irish market — 10,165 products with active substances, licence holders, dosage forms and prescription status.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9
413 medicines starting with “B”
MedicineActive substanceLicence holderStatus
Bisoprolol Viatris 2.5 mg film-coated tablets
PA23266/055/002
BISOPROLOL FUMARATE Viatris Limited Marketed
Bisoprolol Viatris 3.75 mg film-coated tablets
PA23266/055/003
BISOPROLOL FUMARATE Viatris Limited Not marketed
Bisoprolol Viatris 5 mg film-coated tablets
PA23266/055/004
BISOPROLOL FUMARATE Viatris Limited Marketed
Bisoprolol Viatris 7.5 mg film-coated tablets
PA23266/055/005
BISOPROLOL FUMARATE Viatris Limited Marketed
Bisoprolol Zentiva 1.25mg tablets
PA1701/010/001
BISOPROLOL FUMARATE Zentiva k.s. Marketed
Bisoprolol Zentiva 10 mg tablets
PA1701/010/006
BISOPROLOL FUMARATE Zentiva k.s. Marketed
Bisoprolol Zentiva 2.5mg tablets
PA1701/010/002
BISOPROLOL FUMARATE Zentiva k.s. Marketed
Bisoprolol Zentiva 3.75mg tablets
PA1701/010/003
BISOPROLOL FUMARATE Zentiva k.s. Marketed
Bisoprolol Zentiva 5mg tablets
PA1701/010/004
BISOPROLOL FUMARATE Zentiva k.s. Marketed
Bisoprolol Zentiva 7.5mg tablets
PA1701/010/005
BISOPROLOL FUMARATE Zentiva k.s. Marketed
Bisoprololhemifumaraat Genthon 10 mg, film-coated tablets
PA0740/007/002
Bisoprolol hemifumarate Genthon B.V. Not marketed
Bisoprololhemifumaraat Genthon 5 mg film-coated tablets
PA0740/007/001
Bisoprolol hemifumarate Genthon B.V. Not marketed
Bitifrin 0.3 mg/ml + 5 mg/ml eye drops, solution
PA1391/005/001
Bimatoprost, Timolol Maleate Farmaprojects S.A.U Not marketed
BLENREP 100 mg powder for concentrate for solution for infusion
EU/1/25/1948/002
Belantamab Mafodotin GlaxoSmithKline Trading Services Limited
BLENREP 70 mg powder for concentrate for solution for infusion
EU/1/25/1948/001
Belantamab Mafodotin GlaxoSmithKline Trading Services Limited
BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion
EU/1/15/1047/001
Blinatumomab Amgen Europe B.V.,
Blissel 50 micrograms/g vaginal gel
PA2102/001/001
Estriol Italfarmaco S.A. Not marketed
Blitzima 100 mg concentrate for solution for infusion
EU/1/17/1205/001-002
Rituximab Celltrion Healthcare Hungary Kft.
Blopress 16 mg Tablets
PA2239/014/004
Candesartan cilexetil CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress 32 mg Tablets
PA2239/014/005
Candesartan cilexetil CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress 4 mg Tablets
PA2239/014/002
Candesartan cilexetil CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress 8 mg Tablets
PA2239/014/003
Candesartan cilexetil CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress Plus 16 mg/12.5 mg tablets
PA2239/015/002
Candesartan cilexetil, Hydrochlorothiazide CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress Plus 32 mg/12.5 mg tablets
PA2239/015/003
Candesartan cilexetil, Hydrochlorothiazide CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress Plus 32 mg/25 mg tablets
PA2239/015/004
Candesartan cilexetil, Hydrochlorothiazide CHEPLAPHARM Arzneimittel GmbH Not marketed
Blopress Plus 8 mg/12.5 mg tablets
PA2239/015/001
Candesartan cilexetil, Hydrochlorothiazide CHEPLAPHARM Arzneimittel GmbH Not marketed
BOCOUTURE 100 units powder for solution for injection
PA1907/003/002
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS Merz Pharmaceuticals GmbH Marketed
BOCOUTURE 50 units powder for solution for injection
PA1907/003/001
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS Merz Pharmaceuticals GmbH Marketed
BOMYNTRA 120 mg solution for injection in pre-filled syringe
EU/1/25/1953/04-06
Denosumab Fresenius Kabi Deutschland GmbH
BOMYNTRA 120 mg solution for injection in vial
EU/1/25/1953/01-03
Denosumab Fresenius Kabi Deutschland GmbH
Bonasol Once Weekly 70 mg Oral Solution
PA1572/001/001
Alendronate sodium trihydrate Xeolas Pharmaceuticals Limited Marketed
Bondronat 2 mg concentrate for solution for infusion.
EU/1/96/012/004
Ibandronic acid monosodium monohydrate Atnahs Pharma Netherlands B.V.
Bondronat 50 mg film-coated tablets
EU/1/96/012/009-010
Ibandronic acid Atnahs Pharma Netherlands B.V.
Bondronat 6 mg concentrate for solution for infusion
EU/1/96/012/011-13
Ibandronic acid Atnahs Pharma Netherlands B.V.
Bonjela Oromucosal Gel Choline Salicylate 8.714% Cetalkonium Chloride 0.010%
PA0979/001/001
Choline salicylate, Cetalkonium chloride Reckitt Benckiser Ireland Limited Marketed
Bonjela Teething Gel Oromucosal Gel Choline Salicylate 8.714% Cetalkonium Chloride 0.010%
PA0979/001/003
Choline salicylate, Cetalkonium chloride Reckitt Benckiser Ireland Limited Marketed
Bonviva 150 mg film-coated tablets
EU/1/03/265/3-4
Ibandronic acid Atnahs Pharma Netherlands B.V.
Bonviva 3 mg solution for injection
EU/1/03/265/5-6
Ibandronic acid Atnahs Pharma Netherlands B.V.
Boostrix suspension for injection in pre-filled syringe Diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed, reduced antigen(s) content)
PA1077/020/001
Pertactin, Filamentous haemagglutinin, Pertussis toxoid, Tetanus toxoid, Diphtheria toxoid GlaxoSmithKline (Ireland) Limited Marketed
Bortezomib 1 mg powder for solution for injection
PA23142/012/001
Bortezomib Aspire Pharma (Malta) Limited Not marketed
Bortezomib 2.5 mg powder for solution for injection
PA23142/012/003
Bortezomib Aspire Pharma (Malta) Limited Not marketed
Bortezomib 2.5 mg/ml solution for injection
PA1774/008/001
Bortezomib EVER Valinject GmbH Marketed
Bortezomib 3.5 mg powder for solution for injection
PA23142/012/002
Bortezomib Aspire Pharma (Malta) Limited Not marketed
Bortezomib 3.5 mg powder for solution for injection
PA23092/003/001
Bortezomib Reddy Holding GmbH
Bortezomib 3.5 mg powder for solution for injection
PA23250/003/001
Bortezomib MSN Labs Europe Limited Marketed
Bortezomib Accord 1 mg Powder for solution for injection
EU/1/15/1019/002
Bortezomib Accord Healthcare S.L.U.
Bortezomib Accord 2.5 mg/ml Solution for injection
EU/1/15/1019/003-006
Bortezomib Accord Healthcare S.L.U.
Bortezomib Accord 3.5 mg Powder for solution for injection
EU/1/15/1019/001
Bortezomib Accord Healthcare S.L.U.
Bortezomib Biotech Pharma 3.5 mg powder for solution for injection
PA25233/001/001
Bortezomib Target Healthcare Limited Not marketed
Bortezomib Clonmel 2.5 mg/ml Solution for Injection
PA0126/297/001
Bortezomib Clonmel Healthcare Ltd Marketed
2 3 4 5 6 7 8

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.